161 related articles for article (PubMed ID: 35801173)
21. The highly selective mGlu
Hamadjida A; Sid-Otmane L; Kwan C; Frouni I; Nafade V; Bédard D; Gagnon D; Wallman MJ; Rouillard C; Parent A; Parent M; Huot P
Eur J Neurosci; 2020 Jun; 51(12):2412-2422. PubMed ID: 31944461
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Muñoz A; Garrido-Gil P; Dominguez-Meijide A; Labandeira-Garcia JL
Exp Neurol; 2014 Nov; 261():720-32. PubMed ID: 25160895
[TBL] [Abstract][Full Text] [Related]
23. The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Wu N; Wan Y; Song L; Qi C; Liu Z; Gan J
Neuropsychiatr Dis Treat; 2018; 14():1779-1786. PubMed ID: 30013350
[TBL] [Abstract][Full Text] [Related]
24. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
[TBL] [Abstract][Full Text] [Related]
25. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE
Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389
[TBL] [Abstract][Full Text] [Related]
26. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
27. Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson's Disease.
Dos Santos Pereira M; Abreu GHD; Rocca J; Hamadat S; Raisman-Vozari R; Michel PP; Del Bel E
Front Pharmacol; 2020; 11():617085. PubMed ID: 33510643
[TBL] [Abstract][Full Text] [Related]
28. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
29. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Aristieta A; Ruiz-Ortega JA; Morera-Herreras T; Miguelez C; Ugedo L
Exp Neurol; 2019 Dec; 322():113036. PubMed ID: 31425688
[TBL] [Abstract][Full Text] [Related]
30. Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats.
Azar YO; Badawi GA; Zaki HF; Ibrahim SM
Life Sci; 2022 Dec; 311(Pt A):121049. PubMed ID: 36209830
[TBL] [Abstract][Full Text] [Related]
31. Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Doo AR; Kim SN; Hahm DH; Yoo HH; Park JY; Lee H; Jeon S; Kim J; Park SU; Park HJ
BMC Complement Altern Med; 2014 Mar; 14():107. PubMed ID: 24650244
[TBL] [Abstract][Full Text] [Related]
32. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
[TBL] [Abstract][Full Text] [Related]
33. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
[TBL] [Abstract][Full Text] [Related]
34. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
35. Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
Kim YK; Lee AR; Park H; Yoo J; Ahn S; Jeon SH; Kim J; Park HJ
Mol Neurobiol; 2019 Apr; 56(4):2408-2423. PubMed ID: 30030752
[TBL] [Abstract][Full Text] [Related]
36. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Yang X; Chen Y; Hong X; Wu N; Song L; Yuan W; Liu Z
Drug Des Devel Ther; 2012; 6():341-7. PubMed ID: 23185117
[TBL] [Abstract][Full Text] [Related]
37. Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
Tronci E; Francardo V
J Neural Transm (Vienna); 2018 Aug; 125(8):1137-1144. PubMed ID: 29242978
[TBL] [Abstract][Full Text] [Related]
38. Effects of Aging on Levo-Dihydroxyphenylalanine- Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Nishijima H; Kimura T; Mori F; Wakabayashi K; Kinoshita I; Nakamura T; Kon T; Suzuki C; Tomiyama M
Front Aging Neurosci; 2021; 13():650350. PubMed ID: 34054505
[TBL] [Abstract][Full Text] [Related]
39. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of glycogen synthase kinase-3β by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes.
Wang HM; Zhang T; Li Q; Huang JK; Chen RF; Sun XJ
Neurochem Int; 2013 Nov; 63(5):345-53. PubMed ID: 23871716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
